Cohort/Ethics Study of Patients With Severe Alcoholic Hepatitis Undergoing Early Liver Transplantation

Sponsor
Johns Hopkins University (Other)
Overall Status
Enrolling by invitation
CT.gov ID
NCT04234139
Collaborator
National Institute on Alcohol Abuse and Alcoholism (NIAAA) (NIH)
300
1
69
4.3

Study Details

Study Description

Brief Summary

The purpose of this study is to develop a clinical understanding of early liver transplantation (ELT) for patients with severe alcoholic hepatitis (SAH) and identify the public's opinion regarding this practice.

Detailed Description

The research study is designed to improve the investigators' understanding of early liver transplantation for patients with severe alcoholic hepatitis. The goal of this research is twofold:

  1. Establish a knowledge base necessary for appropriate liver transplant candidate selection by quantifying post-ELT mortality for SAH and compare to outcomes to liver transplantation for other indications

  2. Develop an ethical framework for implementation of these transplants for SAH based on the opinions of healthcare providers and the general public.

Study Design

Study Type:
Observational
Anticipated Enrollment :
300 participants
Observational Model:
Cohort
Time Perspective:
Other
Official Title:
Cohort/Ethics Study of Patients With Severe Alcoholic Hepatitis Undergoing Early Liver Transplantation
Actual Study Start Date :
Apr 1, 2020
Anticipated Primary Completion Date :
Dec 31, 2025
Anticipated Study Completion Date :
Dec 31, 2025

Arms and Interventions

Arm Intervention/Treatment
Retrospective Cohort

Early Liver Transplantation (ELT) for patients who presented with Severe Alcoholic Hepatitis (SAH)

Procedure: liver transplant
solid organ transplant

Prospective Cohort 1

Early Liver Transplantation (ELT) for patients who present with Severe Alcoholic Hepatitis (SAH)

Procedure: liver transplant
solid organ transplant

Prospective Cohort 2

Orthotopic Liver Transplantation (OLT) in patient who present with Alcoholic Liver Disease (ALD)

Procedure: liver transplant
solid organ transplant

Outcome Measures

Primary Outcome Measures

  1. Number of participants who survived within 1 year post-transplant [1 years]

    Post-transplant survival within one year of the surgical procedure.

Secondary Outcome Measures

  1. Number of participants who self-report or have biochemically measured alcohol recidivism or relapse within 1 year post-transplant [1 years]

    Self-reported or biochemically measured alcohol recidivism or relapse.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria for Severe Alcoholic Hepatitis patients:
  • Patients with Severe Alcoholic Hepatitis (SAH) listed for liver transplantation at Johns Hopkins Hospital (JHH), have not been sober for at least 6 months at time of waitlisting, and are at least 18 years old.
Exclusion Criteria for Severe Alcoholic Hepatitis patients:
  • Non-SAH patients listed for liver transplantation at JHH and patients who have been sober for at least 6 months at the time of waitlisting.
Inclusion Criteria for non-SAH comparison group:
  • Patients 18 years or older undergoing liver transplantation at JHH for alcoholic liver disease and were sober for at least 6 months prior to transplantation.
Exclusion Criteria for non-SAH comparison group:
  • Patients who do not meet inclusion criteria.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Johns Hopkins University Baltimore Maryland United States 21205

Sponsors and Collaborators

  • Johns Hopkins University
  • National Institute on Alcohol Abuse and Alcoholism (NIAAA)

Investigators

  • Principal Investigator: Andrew M Cameron, MD, PhD, Johns Hopkins University

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Johns Hopkins University
ClinicalTrials.gov Identifier:
NCT04234139
Other Study ID Numbers:
  • IRB00154881
  • P50AA027054
First Posted:
Jan 21, 2020
Last Update Posted:
Apr 7, 2022
Last Verified:
Apr 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Johns Hopkins University
Additional relevant MeSH terms:

Study Results

No Results Posted as of Apr 7, 2022